Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (42)	3/18/2002 6:19:38 PM
From: Biomaven	Read Replies (1) \| Respond to of 510

tuck, Thanks. I still don't know the exact relationship between Lumisys, CTI and MAS - I'm guessing they can be considered a single entity controlled by the original inventor. So if we restrict ourselves to drug discovery products, then it appears that Ciphergen can make, use and exclusively sell them, while CTI (and hence Lumisys) can only make or use them. If that's right, it's likely all going to turn on whether information is a "drug discovery product." Personally, I would say it is. I did take a brief look at the abstracts - as you say, much more than ovarian cancer. Peter

To: tuck who wrote (42)	3/18/2002 6:19:46 PM
From: tuck	Respond to of 510

Followup: If you do the search described at the bottom of the previous post, you will find 17 presentations at AACR involving SELDI. All 17 are affiliated with Ciphergen customers, as matched by the customer list in the S-1, case studies from the CIPH website, or obvious reference to the chips used in the body of the abstract. A couple involve looking for multiple pathways. The rest involve biomarkers for various cancers: Breast Ovarian Prostate Renal Cell Carcinoma Transitional Cell Carcinoma Colon Lung Bladder Plus one dealing with hypoxia, and another dealing with carcinogens in cooked meat. Cheers, Tuck